Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?

Autor:	Hyytiäinen A; Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Helsinki, Finland.; Translational Immunology Programme, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Wahbi W; Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Helsinki, Finland.; Translational Immunology Programme, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Väyrynen O; Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Helsinki, Finland., Saarilahti K; Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Karihtala P; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki, Helsinki, Finland., Salo T; Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Helsinki, Finland.; Translational Immunology Programme, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Pathology, University of Helsinki, Helsinki, Finland.; Cancer Research and Translational Medicine Research Unit, University of Oulu, Oulu, Finland.; Oulu Medical Research Centre, Oulu University Hospital, University of Oulu, Oulu, Finland., Al-Samadi A; Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Helsinki, Finland.; Translational Immunology Programme, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2021 Jun 14; Vol. 11, pp. 683570. Date of Electronic Publication: 2021 Jun 14 (Print Publication: 2021).
DOI:	10.3389/fonc.2021.683570
Abstrakt:	Background: Head and neck squamous cell carcinoma (HNSCC) carries poor survival outcomes despite recent progress in cancer treatment in general. Angiogenesis is crucial for tumour survival and progression. Therefore, several agents targeting the pathways that mediate angiogenesis have been developed. We conducted a systematic review to summarise the current clinical trial data examining angiogenesis inhibitors in HNSCC. Methods: We carried out a literature search on three angiogenesis inhibitor categories-bevacizumab, tyrosine kinase inhibitors and endostatin-from Ovid MEDLINE, Cochrane Library, Scopus and ClinicalTrials.gov database. Results: Here, we analysed 38 clinical trials, total of 1670 patients, investigating 12 angiogenesis inhibitors. All trials were in phase I or II, except one study in phase III on bevacizumab. Angiogenesis inhibitors were used as mono- and combination therapies together with radio-, chemo-, targeted- or immunotherapy. Among 12 angiogenesis inhibitors, bevacizumab was the most studied drug, included in 13 trials. Although bevacizumab appeared effective in various combinations, it associated with high toxicity levels. Endostatin and lenvatinib were well-tolerated and their anticancer effects appeared promising. Conclusions: Most studies did not show benefit of angiogenesis inhibitors in HNSCC treatment. Additionally, angiogenesis inhibitors were associated with considerable toxicity. However, some results appear encouraging, suggesting that further investigations of angiogenesis inhibitors, particularly in combination therapies, for HNSCC patients are warranted. Systematic Review Registration: PROSPERO (https://www.crd.york.ac.uk/prospero/), identifier CRD42020157144. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Hyytiäinen, Wahbi, Väyrynen, Saarilahti, Karihtala, Salo and Al-Samadi.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu